MannKind | MNKD - Заемный капитал





Заемный капитал Изменить Дата
Adma Biologics USD 69.33M 750K 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Insmed USD 540.96M 1.24M 2025-12
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
MacroGenics USD 70M 256K 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Novavax USD 246.3M 200K 2025-12
Novo Nordisk DKK 14.02B 224.49M 2025-09
Pfizer USD 57.41B 93M 2025-09
Sanofi EUR 13.84B 1.88B 2026-03
Xencor USD 76.48M 11.29M 2025-12